Pushing mRNA therapeutics for cancer, Cambridge startup nabs Series A to explore next-gen approach
With increased interest in mRNA therapeutics thanks to Pfizer and Moderna’s megablockbuster Covid-19 vaccines, a new startup located next to MIT is getting infused with cash as it looks to go into the clinic.
Kernal Bio put out word Thursday morning that it had completed a $25 million Series A round, led by Hummingbird Ventures. The new capital, which should last Kernal about two and a half years, will extend Kernal’s “mRNA 2.0” platform and support an IND filing for Kernal’s I/O candidate KR-335.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.